Clinical decisions should be based on the different molecular subtypes of pRCC; therefore, sensitivity to the 30 common anti-tumour drugs was compared between the high– and low–SHMT2 expression groups to determine potential treatment modalities for pRCC. This evidence concerns the gene PRCC and neoplasm.